
One infusion, a permanent edit: what gene editing for cholesterol has measured so far
VERVE-102 and CTX310 edit liver genes to lower LDL cholesterol after a single infusion. The 2026 papers report large drops in a few dozen selected patients — open-label, no placebo, and not one cardiovascular event counted.







